treatment options for patients who progress on enfortumab vedotin | arjun balar
Published 3 years ago • 77 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
3:14
the role of enfortumab vedotin in earlier lines and stages of urothelial cancer | arjun balar
-
4:15
ev-201: enfortumab an option for cisplatin-ineligible advanced uc | arjun balar
-
4:38
ev-301: enfortumab vedotin boosts advanced urothelial cancer survival | thomas powles
-
27:26
advanced bladder cancer: dr. arjun balar talks treatment strategies in a changing field
-
1:39
phase ib trial of bintrafusp alfa for advanced urothelial cancer
-
3:41
outcomes of pts w/metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin
-
2:36
asco gu 2019 - dr. arjun v balar, nyu langone's pearlmutter cancer center, usa
-
34:39
bladder cancer and immunotherapy with dr. arjun balar
-
6:47
immunotherapy and the side effects
-
11:29
enfortumab vedotin plus pembrolizumab: results of the ev-302 trial with thomas powles, md
-
2:49
immunotherapy for bladder cancer
-
1:06
arjun balar, m.d., discusses future of immunotherapy
-
22:49
update on precision medicine & bladder cancer | developments in targeted therapy
-
47:59
advances in bladder cancer immunotherapy, with dr. arjun balar
-
13:47
ev-103: enfortumab vedotin and pembrolizumab in urothelial carcinoma
-
14:16
new emerging treatment options and targeted therapies for bladder cancer
-
54:16
current treatment options and things to consider for myelofibrosis patients with anand patel, md
-
1:09
dr. balar on improved outlook in metastatic bladder cancer
-
6:58
promising treatment options for advanced bladder cancer
-
0:51
dr. balar on the approval of pembrolizumab for bladder cancer
-
37:11
sequencing of agents and combination of treatment options for bladder cancer
-
6:39
induce-1 points to icos agonist activity in advanced urothelial cancer | arjun balar